BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16258068)

  • 21. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells.
    Piek E; Moustakas A; Kurisaki A; Heldin CH; ten Dijke P
    J Cell Sci; 1999 Dec; 112 ( Pt 24)():4557-68. PubMed ID: 10574705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of transforming growth factor-beta signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGF beta type I receptor kinase.
    Yakymovych I; Engström U; Grimsby S; Heldin CH; Souchelnytskyi S
    Biochemistry; 2002 Sep; 41(36):11000-7. PubMed ID: 12206672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation.
    Tognon C; Garnett M; Kenward E; Kay R; Morrison K; Sorensen PH
    Cancer Res; 2001 Dec; 61(24):8909-16. PubMed ID: 11751416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures.
    Wilkes MC; Leof EB
    J Biol Chem; 2006 Sep; 281(38):27846-54. PubMed ID: 16867995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling.
    Blobe GC; Schiemann WP; Pepin MC; Beauchemin M; Moustakas A; Lodish HF; O'Connor-McCourt MD
    J Biol Chem; 2001 Jul; 276(27):24627-37. PubMed ID: 11323414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenoviral gene transfer allows Smad-responsive gene promoter analyses and delineation of type I receptor usage of transforming growth factor-beta family ligands in cultured human granulosa luteal cells.
    Kaivo-Oja N; Mottershead DG; Mazerbourg S; Myllymaa S; Duprat S; Gilchrist RB; Groome NP; Hsueh AJ; Ritvos O
    J Clin Endocrinol Metab; 2005 Jan; 90(1):271-8. PubMed ID: 15483083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
    Wendt MK; Schiemann WP
    Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of a serine/threonine kinase signaling pathway by transforming growth factor type beta.
    Atfi A; Lepage K; Allard P; Chapdelaine A; Chevalier S
    Proc Natl Acad Sci U S A; 1995 Dec; 92(26):12110-4. PubMed ID: 8618854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
    Inman GJ; Nicolás FJ; Callahan JF; Harling JD; Gaster LM; Reith AD; Laping NJ; Hill CS
    Mol Pharmacol; 2002 Jul; 62(1):65-74. PubMed ID: 12065756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TGF-beta-mediated activation of RhoA signalling is required for efficient (V12)HaRas and (V600E)BRAF transformation.
    Fleming YM; Ferguson GJ; Spender LC; Larsson J; Karlsson S; Ozanne BW; Grosse R; Inman GJ
    Oncogene; 2009 Feb; 28(7):983-93. PubMed ID: 19079344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src.
    Jin W; Yun C; Hobbie A; Martin MJ; Sorensen PH; Kim SJ
    Cancer Res; 2007 Apr; 67(7):3192-200. PubMed ID: 17409427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CHIP controls the sensitivity of transforming growth factor-beta signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation.
    Xin H; Xu X; Li L; Ning H; Rong Y; Shang Y; Wang Y; Fu XY; Chang Z
    J Biol Chem; 2005 May; 280(21):20842-50. PubMed ID: 15781469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Smad2/Smad3 in endothelium is indispensable for vascular stability via S1PR1 and N-cadherin expressions.
    Itoh F; Itoh S; Adachi T; Ichikawa K; Matsumura Y; Takagi T; Festing M; Watanabe T; Weinstein M; Karlsson S; Kato M
    Blood; 2012 May; 119(22):5320-8. PubMed ID: 22498737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.
    Galliher AJ; Schiemann WP
    Cancer Res; 2007 Apr; 67(8):3752-8. PubMed ID: 17440088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PDGF receptor-α promotes TGF-β signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-β receptors.
    Liu C; Li J; Xiang X; Guo L; Tu K; Liu Q; Shah VH; Kang N
    Am J Physiol Gastrointest Liver Physiol; 2014 Oct; 307(7):G749-59. PubMed ID: 25169976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region.
    Wieser R; Attisano L; Wrana JL; Massagué J
    Mol Cell Biol; 1993 Dec; 13(12):7239-47. PubMed ID: 8246946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling.
    Fanayan S; Firth SM; Baxter RC
    J Biol Chem; 2002 Mar; 277(9):7255-61. PubMed ID: 11751851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
    Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
    Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor.
    Rotzer D; Roth M; Lutz M; Lindemann D; Sebald W; Knaus P
    EMBO J; 2001 Feb; 20(3):480-90. PubMed ID: 11157754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.